GlassScriptPhysician profile
Billisha Robinson
NPI 1407394166
$5,876.16
in general payments reported to CMS, 2019-2025
46 companies · $49.15 in 2025
The $49.15 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $867 · 2022: $886 · 2023: $2,339 · 2024: $1,736 · 2025: $49.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.54 |
| Education | $151.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.07 | 2021-2024 | Enhertu, Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $487.37 | 2022-2024 | Opdivo, Augtyro |
| Janssen Biotech, INC. | $406.01 | 2021-2024 | Erleada, Tecvayli, Imbruvica |
| Genzyme Corporation | $403.21 | 2021-2024 | |
| Celgene Corporation | $370.71 | 2021-2024 | Pomalyst, Reblozyl, Opdualag |
| Eisai INC. | $292.13 | 2021-2024 | |
| Incyte Corporation | $289.20 | 2021-2024 | Jakafi, Monjuvi |
| Genmab U.S., INC. | $276.44 | 2023 | Epkinly |
| Novartis Pharmaceuticals Corporation | $265.41 | 2022-2025 | |
| Seagen INC. | $248.01 | 2021-2023 | Tukysa, Padcev, Tivdak |
| Gilead Sciences, INC. | $245.59 | 2021-2024 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $147.75 | 2021-2023 | Imbruvica |
| Daiichi Sankyo INC. | $139.47 | 2021-2024 | Enhertu |
| Abbvie INC. | $136.94 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $128.35 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billisha Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.